Cancer stem cells and radiotherapy
Cancer stem cells and radiotherapy
复制标题
DOI：
10.1080/09553000902836404
复制
发表时间：
2009-01-01
影响因子：
2.6
通讯作者：
Zips, Daniel
中科院分区：
文献类型：
--
作者：
Baumann, Michael;Krause, Mechthild;Zips, Daniel
目的：目前的工作总结了癌症干细胞的放射生物学研究和临床放射肿瘤学的重要性研究的历史和现状。结论：肿瘤干细胞在放射肿瘤学中已成为一个重要的研究领域。定量移植试验与服用剂量50%（TD50）的评价仍然是金标准，以验证所选细胞的干细胞。新技术允许根据肿瘤细胞的表面标志物表达对肿瘤细胞进行分选，从而选择富含癌症干细胞的亚群（例如，例如，在一个实施例中，CD133、CD44、CD29）。尽管基于表面标记的检测方法的发展是肿瘤干细胞研究中非常重要的一步，但迄今为止仍有一些问题有待解决，如：例如，在一个实施例中，标记物的特异性、适当的动物模型和优化的体外测定。放射生物学特别关注的是，体外克隆形成测定不一定测量癌细胞的干性。这阻碍了对癌症干细胞是否比非干细胞更耐辐射这一重要问题的研究。关于这一主题的有限数据中最广泛的涉及通过表面标记CD 133鉴定的胶质瘤干细胞。这并不能为干细胞和非干细胞的放射敏感性差异提供有力的证据。尽管有许多问题需要解决，干细胞标记物与放射生物学检测的结合，为推进放射肿瘤学的转化研究带来了相当大的希望。
Purpose: The present work summarises the history and current status of research into the importance of cancer stem cells for radiobiological research and for clinical radiation oncology. An effort is made to differentiate clonogenicity from stemness of cancer cells.Conclusion: In radiooncology, cancer stem cells have been an important research field for five decades. Quantitative transplantation assays with evaluation of the take dose 50% (TD50) remain the gold standard to verify the stemness of the selected cells. New technologies allow sorting of tumour cells according to their surface marker expression and thereby selecting subpopulations that are enriched in cancer stem cells (e. g., CD133, CD44, CD29). While development of surface-marker-based assays is a highly important step in cancer-stem-cell research, to date there are still problems to be solved, e. g., the specifity of markers, adequate animal models, and optimised in vitro assays. Of special concern for radiobiology is that clonogenic in vitro assays do not necessarily measure stemness of cancer cells. This hampers investigations into the important question of whether cancer stem cells are more radioresistant than non-stem cells. The most extensive of the limited data on this topic relate to glioma stem cells identified by the surface marker CD133. These do not provide firm evidence for difference of radiosensitivity between stem and non stem cells. In spite of many problems to be solved, the combination of stem cell markers with radiobiological assays bears considerable promise for advancing translational research in radiation oncology.